Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 68-75 |
| Number of pages | 8 |
| Journal | Hematological Oncology |
| Volume | 36 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. / Luminari, S; Viel, E; Ferreri, AJM; Zaja, F; Chimienti, E; Musuraca, G; Tucci, Alessandra; Balzarotti, M; Tani, Monica; Salvi, F; Pesce, EA; Ferrari, A; Liberati, Anna Maria; Spadea, A; Marino, D; Bruno-Ventre, M; Volpetti, Stefano; Bottelli, Chiara; Ravaioli, E; Merli, F; Spina, M.
In: Hematological Oncology, Vol. 36, No. 1, 2018, p. 68-75.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
AU - Luminari, S
AU - Viel, E
AU - Ferreri, AJM
AU - Zaja, F
AU - Chimienti, E
AU - Musuraca, G
AU - Tucci, Alessandra
AU - Balzarotti, M
AU - Tani, Monica
AU - Salvi, F
AU - Pesce, EA
AU - Ferrari, A
AU - Liberati, Anna Maria
AU - Spadea, A
AU - Marino, D
AU - Bruno-Ventre, M
AU - Volpetti, Stefano
AU - Bottelli, Chiara
AU - Ravaioli, E
AU - Merli, F
AU - Spina, M
PY - 2018
Y1 - 2018
N2 - The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76Â years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF
AB - The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76Â years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF
U2 - 10.1002/hon.2425
DO - 10.1002/hon.2425
M3 - Article
VL - 36
SP - 68
EP - 75
JO - Hematological Oncology
JF - Hematological Oncology
SN - 0278-0232
IS - 1
ER -